|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim was to investigate the potential role of a ClC-2 chloride channel activator, lubiprostone, which is reported to have beneficial effects on LGS, in the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice.
|
31206525 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our aim was to investigate the potential role of a ClC-2 chloride channel activator, lubiprostone, which is reported to have beneficial effects on LGS, in the development of atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice.
|
31206525 |
2019 |
|
Hyperaldosteronism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the adrenal, ClC-2 has been demonstrated to localize predominantly to the zona glomerulosa (ZG), and functional analysis suggests that mutations in ClC-2 predispose ZG cells to depolarization, thus leading to calcium influx via activation of voltage-gated calcium channels and increased aldosterone production.
|
30949771 |
2019 |
|
Complete hydatidiform mole
|
0.010 |
Biomarker
|
disease |
BEFREE |
Paraffin-embedded tissues from CHMs and control placentas were used for tissue microarray (TMA) construction, immunohistochemistry, and immunoscoring for galectin-14.
|
31658584 |
2019 |
|
early pregnancy
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, these results show that Gal-13 and Gal-14 already provide an immunoprivileged environment at the maternal-fetal interface during early pregnancy, and their reduced expression is related to miscarriages.
|
31275299 |
2019 |
|
Conn Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We now show that almost all known PA-associated CLCN2 mutations markedly increase ClC-2 chloride currents and generate knock-in mice expressing a constitutively open ClC-2 Cl<sup>-</sup> channel as mouse model for PA.
|
31615979 |
2019 |
|
Familial Hyperaldosteronism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Elevated aldosterone and blood pressure in a mouse model of familial hyperaldosteronism with ClC-2 mutation.
|
31727896 |
2019 |
|
Parasitic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The involvement of ruminant-specific galectin-11 (LGALS-11) and galectin-14 (LGALS-14) has been postulated to play important roles in protective immune responses against parasitic infection; however, their ligands are unknown.
|
29576976 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
|
29550812 |
2018 |
|
Parasitic infection
|
0.010 |
Biomarker
|
group |
BEFREE |
The involvement of ruminant-specific galectin-11 (LGALS-11) and galectin-14 (LGALS-14) has been postulated to play important roles in protective immune responses against parasitic infection; however, their ligands are unknown.
|
29576976 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
AngII-induced HBVSMC proliferation, migration and invasion were significantly attenuated by ClC-2 downregulation.
|
29988306 |
2018 |
|
Nonalcoholic Steatohepatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ClC-2 mRNA level was significantly increased in patients with non-alcoholic steatohepatitis, which positively correlated with the plasma levels of alanine transaminase (ALT), aspartate transaminase (AST) and insulin.
|
29550812 |
2018 |
|
Gestational Diabetes
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Our results showed that ClC-2 mRNA and protein expressions in GDM group were significantly increased in white matter of fetal rats after E18 stage, and elevated the level of TNF-α and iNOS in white matter at P0 and P3 stage of newborn rats.
|
28255270 |
2017 |
|
Chronic idiopathic constipation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women.
|
28849329 |
2017 |
|
Opioid-Induced Constipation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women.
|
28849329 |
2017 |
|
Irritable bowel syndrome with constipation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women.
|
28849329 |
2017 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Modified AS1411-aptamer suppressed HCC cell growth in vitro and in vivo by up-regulating galectin-14 expressions.
|
27494117 |
2016 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The role of ClC-2 was investigated in TJ barrier function in dextran sodium sulfate (DSS)-induced colitis in ClC-2 knockout mice and ClC-2 knockdown intestinal Caco-2 cells.
|
24030525 |
2013 |
|
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, ClC-2 expression is markedly reduced in the colon of human patients with ulcerative colitis.
|
24030525 |
2013 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
We assessed the localisation of ClC-2 with immunohistochemistry and electron microscopy in post-mortem human brains of individuals without neurological disorders.
|
23707145 |
2013 |
|
Glaucoma, Primary Open Angle
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, CLC‑2 may be a promising and potential novel therapeutic strategy for combating primary open‑angle glaucoma.
|
23934342 |
2013 |
|
Channelopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
Nearly every aspect of ClC-2 is discussed in the review: molecular features, biophysical characteristics, pharmacological properties, cellular function, regulation of expression and function, and channelopathies.
|
24378849 |
2013 |
|
Constipation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lubiprostone, used clinically (b.i.d.) to treat constipation, has been reported to increase transepithelial Cl(-) transport in T84 cells by activating ClC-2 channels.
|
21140215 |
2011 |
|
Epilepsy, Generalized
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Functional evaluation of human ClC-2 chloride channel mutations associated with idiopathic generalized epilepsies.
|
15252188 |
2004 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Fisher's analysis within this data set, did not demonstrate a significant relationship between the severity of lung disease and SNPs in the CLC-2 gene.
|
15507145 |
2004 |